On Tuesday, the Senate Health committee held a hearing on the promise of precision medicine. Last week, the House released draft legislation to support biomedical innovation. And following President Obama’s State of the Union in January, the White House unveiled the Precision Medicine Initiative, meant to provide funding to accelerate biomedical research.
What none of these things do directly is to curb the price of speciality drugs—including precision drugs—which cost Americans more than $80 billion in 2013, according to the Campaign for Sustainable Rx Pricing.
{iframe}http://www.nationaljournal.com/health-care/washington-s-interest-in-precision-drugs-is-innovation-not-cost-20150505{/iframe}